Integrated systems biology approach reveals the potential mechanism of Guanxinning in treating coronary heart disease complicated with major depressive disorder through S1PR3 regulation

This study identifies S1PR3 as a critical therapeutic target for the comorbidity of CHD and MDD. GXN has the potential to treat CHD and MDD by regulating S1PR3 expression levels. Although further validation through animal and cell-based experiments is needed, our findings provide a foundational understanding of the molecular mechanisms and highlight the therapeutic potential of GXN in dual heart therapy.